BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Felzartamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Felzartamab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06685757-3402@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Felzartamab: Phase 3 readout est. (NCT06685757)
DESCRIPTION:Felzartamab\, phase 3.\nStudy: A Study to Learn More About the 
 Effects and Safety of Felzartamab Infusions in Adults With Kidney Transpla
 nts Who Have Antibody-Mediated Rejection (AMR)\nEstimated primary completi
 on: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 felzartamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06685757
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06935357-3402@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Felzartamab: Phase 3 readout est. (NCT06935357)
DESCRIPTION:Felzartamab\, phase 3\, IgA Nephropathy.\nStudy: A Study to Lea
 rn About the Effects of Felzartamab Infusions on Adults With Immunoglobuli
 n A Nephropathy (IgAN)\nEstimated primary completion: 31 May 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/felzartamab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06935357
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722546-3402@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Felzartamab: Phase 2 readout est. (NCT07722546)
DESCRIPTION:Felzartamab\, phase 2.\nStudy: A Study to Learn About The Effec
 ts of Felzartamab on Thyroid Function and Its Safety in Adults With Graves
 ' Disease Ages 18 to 75 Years Old\nEstimated primary completion: 31 Januar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/felzartamab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07722
 546
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219043-3402@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20280210
DTEND;VALUE=DATE:20280211
SUMMARY:Felzartamab: Phase 2 readout est. (NCT07219043)
DESCRIPTION:Felzartamab\, phase 2.\nStudy: A Study to Learn About the Effec
 ts of Felzartamab Infusions in Adults With Kidney Transplants Who Have Lat
 e Isolated Microvascular Inflammation\nEstimated primary completion: 10 Fe
 bruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/felzarta
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07219043
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07889362-3402@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20280813
DTEND;VALUE=DATE:20280814
SUMMARY:Felzartamab: Phase 2 readout est. (NCT07889362)
DESCRIPTION:Felzartamab\, phase 2\, IgA Nephropathy.\nStudy: A Study to Lea
 rn About the Effects of Felzartamab on the Kidneys of Adults With Immunogl
 obulin A Nephropathy (IgAN)\nEstimated primary completion: 13 August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/felzartamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07889362
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07939802-3402@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20280919
DTEND;VALUE=DATE:20280920
SUMMARY:Felzartamab: Phase 2 readout est. (NCT07939802)
DESCRIPTION:Felzartamab\, phase 2.\nStudy: A Study to Learn About the Effec
 ts of Felzartamab on Daily Living Activities and Its Safety in Adults With
  Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old\nEstimated pr
 imary completion: 19 September 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/felzartamab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07939802
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962800-3402@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20300128
DTEND;VALUE=DATE:20300129
SUMMARY:Felzartamab: Phase 3 readout est. (NCT06962800)
DESCRIPTION:Felzartamab\, phase 3\, Primary Membranous Nephropathy.\nStudy:
  A Study to Learn More About the Effects and Safety of Felzartamab Infusio
 ns in Adults With Primary Membranous Nephropathy (PMN)\nEstimated primary 
 completion: 28 January 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/felzartamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06962800
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444489-3402@assetmemo.bio
DTSTAMP:20261121T004116Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Felzartamab: Phase 3 readout est. (NCT07444489)
DESCRIPTION:Felzartamab\, phase 3.\nStudy: A Study to Learn More About the 
 Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidne
 y Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular 
 Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)\nEstimated primary completion
 : 31 December 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/f
 elzartamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07444489
URL:https://assetmemo.bio/drug/felzartamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
